Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04430712 · ClinicalTrials.gov registry record
Immune Checkpoint Inhibitors and Atherosclerotic Plaque Volume
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 60
- Enrollment target
NCT04430712: Completed study, sponsored by Massachusetts General Hospital.
NCT04430712 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04430712 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 60 participants
- Enrollment target
Study Summary
In this study, investigators plan to test whether Immune Checkpoint Inhibitor (ICI) treatment leads to an accelerated progression of atherosclerosis in patients with lung cancer. Atherosclerosis is an immune-mediated inflammatory disease and these same checkpoints being targeted for cancer are critical negative regulators of atherosclerosis in animal and cellular models. Aortic plaque progression will be compared between cases (on ICI) and controls from pre-ICI to post-ICI among patients with non-small cell lung cancer. Groups will be matched for age, cancer type and stage and cardiovascular risk factors. Traditional markers of cardiovascular (CVD) risk and cancer-specific factors (ICI mono- and combination therapy, number of cycles, occurrence of immune-related adverse events, chest radiation, steroid use) will be associated with the change in aortic plaque volume.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2020-08-01 |
| Est. Completion | 2022-08-22 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04430712
The ClinicalTrials.gov registry entry for NCT04430712 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04430712 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04430712 about?
NCT04430712 is a clinical study titled "Immune Checkpoint Inhibitors and Atherosclerotic Plaque Volume". In this study, investigators plan to test whether Immune Checkpoint Inhibitor (ICI) treatment leads to an accelerated progression of atherosclerosis in patients with lung cancer. Atherosclerosis is an immune-mediated inflammatory disease and these same checkpoints being targeted for cancer are criti...
What is the current status of trial NCT04430712?
This trial is currently completed. The enrollment target is 60 participants. The study started on 2020-08-01. Estimated completion is 2022-08-22.
Who is sponsoring clinical trial NCT04430712?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.